354 related articles for article (PubMed ID: 28412911)
1. Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update.
Wang YD; Liu ZJ; Ren J; Xiang MX
Curr Vasc Pharmacol; 2018 Jan; 16(2):114-124. PubMed ID: 28412911
[TBL] [Abstract][Full Text] [Related]
2. Challenges and opportunities in limiting abdominal aortic aneurysm growth.
Golledge J; Norman PE; Murphy MP; Dalman RL
J Vasc Surg; 2017 Jan; 65(1):225-233. PubMed ID: 27641464
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment of abdominal aortic aneurysm.
Miyake T; Morishita R
Cardiovasc Res; 2009 Aug; 83(3):436-43. PubMed ID: 19454489
[TBL] [Abstract][Full Text] [Related]
4. Potential Medication Treatment According to Pathological Mechanisms in Abdominal Aortic Aneurysm.
Zhang SL; Du X; Chen YQ; Tan YS; Liu L
J Cardiovasc Pharmacol; 2018 Jan; 71(1):46-57. PubMed ID: 28953105
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol Inhibits Growth of Experimental Abdominal Aortic Aneurysm Associated With Upregulation of Angiotensin-Converting Enzyme 2.
Moran CS; Biros E; Krishna SM; Wang Y; Tikellis C; Morton SK; Moxon JV; Cooper ME; Norman PE; Burrell LM; Thomas MC; Golledge J
Arterioscler Thromb Vasc Biol; 2017 Nov; 37(11):2195-2203. PubMed ID: 28935757
[TBL] [Abstract][Full Text] [Related]
6. Current Theories and Clinical Trial Evidence for Limiting Human Abdominal Aortic Aneurysm Growth.
Yu J; Liu S; Huang J; Wang W
Curr Drug Targets; 2018; 19(11):1302-1308. PubMed ID: 29141546
[TBL] [Abstract][Full Text] [Related]
7. The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms.
VAN KUIJK JP; FLU WJ; WITTEVEEN OP; VOUTE M; BAX JJ; POLDERMANS D
J Cardiovasc Surg (Torino); 2009 Oct; 50(5):599-609. PubMed ID: 19741575
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype.
Mukherjee K; Gitlin JM; Loftin CD
J Cardiovasc Pharmacol; 2012 Dec; 60(6):520-9. PubMed ID: 22967986
[TBL] [Abstract][Full Text] [Related]
9. Optimal Time for Pharmacological Treatment of Abdominal Aortic Aneurysm.
Iida Y; Sawa S; Shimizu H
Curr Drug Targets; 2018; 19(11):1297-1301. PubMed ID: 29284387
[TBL] [Abstract][Full Text] [Related]
10. Medical management of abdominal aortic aneurysms.
Weiss N; Rodionov RN; Mahlmann A
Vasa; 2014 Nov; 43(6):415-21. PubMed ID: 25339159
[TBL] [Abstract][Full Text] [Related]
11. Abdominal aortic aneurysm: update on pathogenesis and medical treatments.
Golledge J
Nat Rev Cardiol; 2019 Apr; 16(4):225-242. PubMed ID: 30443031
[TBL] [Abstract][Full Text] [Related]
12. Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture.
Fraga-Silva RA; Trachet B; Stergiopulos N
Curr Pharm Des; 2015; 21(28):4000-6. PubMed ID: 26306842
[TBL] [Abstract][Full Text] [Related]
13. Can pharmacologic agents slow abdominal aortic aneurysm growth?
Samson R
Semin Vasc Surg; 2012 Mar; 25(1):25-8. PubMed ID: 22595478
[TBL] [Abstract][Full Text] [Related]
14. Novel pharmacological approaches in abdominal aortic aneurysm.
Puertas-Umbert L; Almendra-Pegueros R; Jiménez-Altayó F; Sirvent M; Galán M; Martínez-González J; Rodríguez C
Clin Sci (Lond); 2023 Aug; 137(15):1167-1194. PubMed ID: 37559446
[TBL] [Abstract][Full Text] [Related]
15. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance.
Thompson A; Cooper JA; Fabricius M; Humphries SE; Ashton HA; Hafez H
J Vasc Surg; 2010 Jul; 52(1):55-61.e2. PubMed ID: 20620765
[TBL] [Abstract][Full Text] [Related]
16. Allergic Lung Inflammation Aggravates Angiotensin II-Induced Abdominal Aortic Aneurysms in Mice.
Liu CL; Wang Y; Liao M; Wemmelund H; Ren J; Fernandes C; Zhou Y; Sukhova GK; Lindholt JS; Johnsen SP; Zhang JY; Cheng X; Huang X; Daugherty A; Levy BD; Libby P; Shi GP
Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):69-77. PubMed ID: 26543094
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Kinin B2 Receptor Signaling Controls Aortic Dilatation and Rupture in the Angiotensin II-Infused Apolipoprotein E-Deficient Mouse.
Moran CS; Rush CM; Dougan T; Jose RJ; Biros E; Norman PE; Gera L; Golledge J
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):898-907. PubMed ID: 26966276
[TBL] [Abstract][Full Text] [Related]
18. Targets for medical therapy to limit abdominal aortic aneurysm progression.
Emeto TI; Seto SW; Golledge J
Curr Drug Targets; 2014; 15(9):860-73. PubMed ID: 25090988
[TBL] [Abstract][Full Text] [Related]
19. Novel insight into the pathobiology of abdominal aortic aneurysm and potential future treatment concepts.
Diehm N; Dick F; Schaffner T; Schmidli J; Kalka C; Di Santo S; Voelzmann J; Baumgartner I
Prog Cardiovasc Dis; 2007; 50(3):209-17. PubMed ID: 17976505
[TBL] [Abstract][Full Text] [Related]
20. Medical management of abdominal aortic aneurysm.
Golledge J; Powell JT
Eur J Vasc Endovasc Surg; 2007 Sep; 34(3):267-73. PubMed ID: 17540588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
